RxDoctor Payments Data

Warren Wisnoff, DO

Internal Medicine · Bakersfield, CANPI 1619956927

Payments from drug & device makers

$1,125in general payments, 2019–2025

Across 55 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$206
  • Medtronic$116
  • Astellas Pharma US Inc$115
  • Pfizer$106
  • Johnson & Johnson$66
  • Cvrx, Inc.$56
  • plus $461 from 16 others

What the payments were for

  • Food & beverage$1,125100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,125 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$281,634
Medicare patients
620
Services billed
3,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin21$17,326
MounjaroTirzepatide12$11,812
EliquisApixaban18$9,283
Enoxaparin Sodium12$2,233
Albuterol Sulfate HfaAlbuterol Sulfate27$1,064
Gabapentin34$721
Levothyroxine Sodium52$499
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$324
Amlodipine Besylate41$251
Fluticasone Propionate28$235
Metoprolol Succinate19$183
Pantoprazole Sodium18$147
Tamsulosin Hcl33$114
Losartan Potassium31$71
Atorvastatin Calcium24$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$45$11,81212 claims
PfizerEliquis$106$9,28318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →